Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations

Antimicrobial Agents and Chemotherapy
M A Encalada VenturaJ W C Alffenaar

Abstract

Voriconazole (VCZ) exhibits great inter- and intrapatient variability. The latter variation cannot exclusively be explained by concomitant medications, liver disease or dysfunction, and genetic polymorphisms in cytochrome P450 2C19 (CYP2C19). We hypothesized that inflammatory response in patients under VCZ medication might also influence this fluctuation in concentrations. In this study, we explored the association between inflammation, reflected by the C-reactive protein (CRP) concentration, and VCZ trough concentrations over time. A retrospective analysis of data was performed for patients with more than one steady-state VCZ trough concentration and a CRP concentration measured on the same day. A longitudinal analysis was used for series of observations obtained from many study participants over time. The approach involved inclusion of random effects and autocorrelation in linear models to reflect within-person cross-time correlation. A total of 50 patients were eligible for the study, resulting in 139 observations (paired VCZ and CRP concentrations) for the analysis, ranging from 2 to 6 observations per study participant. Inflammation, marked by the CRP concentration, had a significant association with VCZ trough concentrati...Continue Reading

References

Jul 18, 2002·Antimicrobial Agents and Chemotherapy·L PurkinsD Kleinermans
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·R HylandD A Smith
May 21, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·S J RoffeyN Wood
Nov 18, 2003·British Journal of Clinical Pharmacology·Lynn PurkinsDon Nichols
Nov 18, 2003·British Journal of Clinical Pharmacology·Lynn PurkinsStuart D Oliver
Sep 1, 2004·The Journal of Biological Chemistry·Steven BlackDavid Samols
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Alison E AitkenEdward T Morgan
Mar 28, 2006·International Journal of Antimicrobial Agents·Dominique LevêqueRaoul Herbrecht
Jun 29, 2006·Clinical Pharmacokinetics·Ursula TheuretzbacherHartmut Derendorf
Jul 26, 2006·Expert Opinion on Drug Metabolism & Toxicology·Kenneth W Renton
Jan 26, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Edward T MorganChristopher J Sinal
Nov 27, 2008·Journal of Clinical Pharmacology·Johanna WeissGerd Mikus
Jan 28, 2009·Antimicrobial Agents and Chemotherapy·Brad MoriyamaThomas J Walsh
Feb 19, 2009·Antimicrobial Agents and Chemotherapy·Steven M TrifilioJayesh Mehta
Apr 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Roger J M BrüggemannDavid M Burger
Apr 30, 2009·Anaesthesia and Intensive Care·K M Ho, J Lipman
Nov 26, 2009·The Journal of Antimicrobial Chemotherapy·Roger J M BrüggemannJ Peter Donnelly
Dec 1, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·J W C AlffenaarD R A Uges
Dec 22, 2009·Expert Opinion on Drug Safety·Alessandro C PasqualottoRafael Linden
Jul 21, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Céline EidenHélène Peyrière
Jul 10, 2014·The Journal of Antimicrobial Chemotherapy·V J C LempersR J M Brüggemann
Sep 17, 2014·Antimicrobial Agents and Chemotherapy·Marjolijn J P van WanrooyJan-Willem C Alffenaar
Dec 19, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rashmi R Shah, Robert L Smith
Mar 4, 2015·Antimicrobial Agents and Chemotherapy·M A Encalada VenturaJ-W C Alffenaar
Apr 18, 2015·Pharmacotherapy·Alice Jenh HsuRavit Arav-Boger

❮ Previous
Next ❯

Citations

Jul 27, 2017·Pharmacogenomics·Elodie Gautier-VeyretFrançoise Stanke-Labesque
Feb 1, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aurélie TruffotElodie Gautier-Veyret
Oct 12, 2018·Fundamental & Clinical Pharmacology·Elodie Gautier-VeyretFrançoise Stanke-Labesque
Dec 12, 2018·British Journal of Clinical Pharmacology·Sara Blanco-DoradoMaría Jesús Lamas
Nov 20, 2016·British Journal of Clinical Pharmacology·Mendy Ter AvestJan-Willem C Alffenaar
May 10, 2020·Intensive Care Medicine·Mohd H Abdul-AzizUNKNOWN Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC)
Jan 29, 2019·Clinical Pharmacokinetics·Changcheng ShiNengming Lin
May 11, 2018·British Journal of Clinical Pharmacology·Bas VreugdenhilRoger J M Brüggemann
Dec 15, 2020·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Eric L PetersonChad L Richardson
Sep 2, 2020·Therapeutic Drug Monitoring·Suyeon KangHye Sun Gwak
Jul 14, 2020·Pharmacology & Therapeutics·Françoise Stanke-LabesqueUNKNOWN French Society of Pharmacology and Therapeutics
May 29, 2021·The Journal of Antibiotics·Takeo YasuTakashi Sugita
Jun 24, 2021·Intensive Care Medicine·Paul E VerweijIgnacio Martin-Loeches
Oct 1, 2021·The Annals of Pharmacotherapy·C Michael White
Dec 20, 2021·Therapeutic Drug Monitoring·Benjamin KablyEliane M Billaud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Antimicrobial Agents and Chemotherapy
Marjolijn J P van WanrooyJan-Willem C Alffenaar
Antimicrobial Agents and Chemotherapy
M A Encalada VenturaJ-W C Alffenaar
Therapeutic Drug Monitoring
Hoan Linh BanhMichael R Sperling
© 2022 Meta ULC. All rights reserved